Oral PCSK9 to drop LDL levels low
Low-density lipoprotein (LDL) cholesterol, popularly known as bad cholesterol is major cause of heart disease. LDL C causes build-up of fatty deposits within arteries, reducing or blocking blood flow thereby causing ischemic strokes and heart attacks. PCSK9 inhibitors work by a mechanism of blocking a liver protein that helps to destroy LDL cholesterol receptors on the surface of cells.The...
Low-density lipoprotein (LDL) cholesterol, popularly known as bad cholesterol is major cause of heart disease. LDL C causes build-up of fatty deposits within arteries, reducing or blocking blood flow thereby causing ischemic strokes and heart attacks. PCSK9 inhibitors work by a mechanism of blocking a liver protein that helps to destroy LDL cholesterol receptors on the surface of cells.
The PCSK9 protein is an important regulator of circulating LDL‐C levels, through its inhibitory action on recycling of the LDL receptor (LDLR). PCSK9 inhibition thus offers a novel therapeutic mechanism for the lowering of LDL‐C levels.
For more details, check out the full story on the link below:
Oral PCSK9 Inhibitor May Significantly Reduce LDL C Levels: DALLAS, The First Human Trial
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd